Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Ethnicity & Disease|July 14, 2011
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Neil Chapman, Choon Lan Chang, Mark Caulfield, et al.
Journal of Hypertension|February 8, 2011
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)David J Collier, Neil R Poulter, Björn Dahlöf, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|February 11, 2005
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter Lindgren, Martin Buxton, Thomas Kahan, et al.
European Heart Journal|September 4, 2012
Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Peter S Sever, Choon L Chang, Margaret F Prescott, et al.
Journal of Hypertension|February 8, 2011
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering ArmDavid J Collier, Neil R Poulter, Björn Dahlöf, et al.
Pharmacoeconomics|April 10, 2009
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1Peter Lindgren, Martin Buxton, Thomas Kahan, et al.
Hypertension (Dallas, Tex. : 1979)|September 2, 2009
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)Charlotte Manisty, Jamil Mayet, Robyn J Tapp, et al.
Heart (British Cardiac Society)|March 26, 2025
Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-upPeter S Sever, Somayeh Rostamian, William Whiteley, et al.
Journal of the American College of Cardiology|August 17, 2013
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering armPeter S Sever, Neil R Poulter, Choon L Chang, et al.
The Lancet. Neurology|March 16, 2010
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of strokePeter M Rothwell, Sally C Howard, Eamon Dolan, et al.
Pageof 9